Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.

Inclusion Criteria: * Male or Female, age 45 years and over. * Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including 1. Vertical supranuclear gaze palsy. 2. Repeated unprovoked falls OR tendency to fall on the pull test within 3 years. * Access to the internet and webcam for virtual visits. * Presence of a caregiver. Exclusion Criteria: * Recent history of significant, uncontrolled GI disease such as Gastroesophageal reflux disease, colorectal cancer. * Significant metabolic or uncontrolled medical comorbidity. * Regular use of typical anti-cholinergic drugs. * Women of child-bearing potential, or who are pregnant and/or nursing. * Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory. * Any other condition or criterion that, in the opinion of the investigators, would preclude safe and meaningful participation in the study.